New Tool Predicts Prostate Cancer Patients' Response to LuPSMA Therapy
A new predictive tool, a nomogram, has been developed to help doctors decide who might benefit from a novel targeted radiation therapy called LuPSMA for advanced metastatic prostate cancer. This therapy, LuPSMA, targets PSMA proteins found in prostate cancer tissue. The tool, created using data from 270 patients, is intended to assist physicians in considering LuPSMA treatment for patients with PSMA-positive metastatic cancer that is resistant to hormone therapy.
The nomogram uses eight parameters, including PSMA PET scan results and clinical factors, to predict survival in response to LuPSMA. It stratifies men into high-risk or low-risk groups based on predicted survival outcomes. In the men studied, those identified as low risk had longer overall survival (24 months) and progression-free survival (6 months) than those classified as high risk (6 months and 2 months, respectively). A web-based risk calculator has been created to forecast the probability of overall and progression-free survival in response to LuPSMA based on the nomogram. However, the tool should be used cautiously and should not replace the clinical judgement of treating physicians until its clinical validity is demonstrated in prospective trials. The research project developing this tool involved collaboration among oncology, urology, and biostatistics departments across multiple institutions, reflecting a collaborative effort among universities, hospitals, and cancer research centers.
The new prognostic tool offers promise in predicting which men with advanced metastatic prostate cancer will respond favorably to LuPSMA therapy. It is intended to assist physicians in considering this treatment option. However, further validation in prospective trials is needed before it can be widely adopted.
